Interaction Checker

Interações de Dasatinibe

Dasatinibe (Sprycel, Phyrago) tem 152 interações documentadas nas bulas da FDA e nas fichas informativas que indexamos (graves: 69; moderadas: 30; leves: 53; casos em que uma bula relata não haver interação significativa: 0). Cada item abaixo cita a frase em que se baseia. Esta página de medicamento é um ponto de partida, não um veredito para a sua situação.

Interações segundo a bula

Interações graves (69)

  • AmiodaronaantiarrítmicoGrave

    Avoid concomitant use of strong CYP3A4 inhibitors. (bula de Dasatinibe, Interações medicamentosas)

  • Antiácidos (Tums, Maalox, Mylanta)Produtos de venda livreGrave

    Antacids: Avoid concomitant use. (bula de Dasatinibe, Interações medicamentosas)

  • Aprepitantoinibidor da CYP3A4Grave

    Avoid concomitant use of strong CYP3A4 inhibitors. (bula de Dasatinibe, Interações medicamentosas)

  • Armodafinilaestimulante do SNCGrave

    If concomitant administration of a strong CYP3A4 inducer cannot be avoided, consider a dose increase [see Dosage and Administration ( 2.3 )] . (bula de Dasatinibe, Interações medicamentosas)

  • AtazanavirantirretroviralGrave

    Avoid concomitant use of strong CYP3A4 inhibitors. (bula de Dasatinibe, Interações medicamentosas)

  • Bicarbonato de sódioantiácidoGrave

    Antacids: Avoid concomitant use. (bula de Dasatinibe, Interações medicamentosas)

  • Bosentanaindutor da CYP3A4Grave

    If concomitant administration of a strong CYP3A4 inducer cannot be avoided, consider a dose increase [see Dosage and Administration ( 2.3 )] . (bula de Dasatinibe, Interações medicamentosas)

  • CarbamazepinaanticonvulsivanteGrave

    If concomitant administration of a strong CYP3A4 inducer cannot be avoided, consider a dose increase [see Dosage and Administration ( 2.3 )] . (bula de Dasatinibe, Interações medicamentosas)

  • CenobamatoanticonvulsivanteGrave

    Avoid concomitant use of strong CYP3A4 inhibitors. (bula de Dasatinibe, Interações medicamentosas)

  • Cetoconazolantifúngico azólicoGrave

    Avoid concomitant use of strong CYP3A4 inhibitors. (bula de Dasatinibe, Interações medicamentosas)

  • CiclosporinaimunossupressorGrave

    Avoid concomitant use of strong CYP3A4 inhibitors. (bula de Dasatinibe, Interações medicamentosas)

  • Cimetidinabloqueador H2Grave

    Avoid concomitant use of strong CYP3A4 inhibitors. (bula de Dasatinibe, Interações medicamentosas)

  • Claritromicinaantibiótico macrolídeoGrave

    Avoid concomitant use of strong CYP3A4 inhibitors. (bula de Dasatinibe, Interações medicamentosas)

  • ClobazambenzodiazepínicoGrave

    If concomitant administration of a strong CYP3A4 inducer cannot be avoided, consider a dose increase [see Dosage and Administration ( 2.3 )] . (bula de Dasatinibe, Interações medicamentosas)

  • DarunavirantirretroviralGrave

    Avoid concomitant use of strong CYP3A4 inhibitors. (bula de Dasatinibe, Interações medicamentosas)

  • Darunavir + cobicistateantirretroviralGrave

    Avoid concomitant use of strong CYP3A4 inhibitors. (bula de Dasatinibe, Interações medicamentosas)

  • Deferasiroxsuplemento de ferroGrave

    If concomitant administration of a strong CYP3A4 inducer cannot be avoided, consider a dose increase [see Dosage and Administration ( 2.3 )] . (bula de Dasatinibe, Interações medicamentosas)

  • DexametasonacorticosteroideGrave

    If concomitant administration of a strong CYP3A4 inducer cannot be avoided, consider a dose increase [see Dosage and Administration ( 2.3 )] . (bula de Dasatinibe, Interações medicamentosas)

  • Diltiazembloqueador dos canais de cálcioGrave

    Avoid concomitant use of strong CYP3A4 inhibitors. (bula de Dasatinibe, Interações medicamentosas)

  • DronedaronaantiarrítmicoGrave

    Avoid concomitant use of strong CYP3A4 inhibitors. (bula de Dasatinibe, Interações medicamentosas)

  • EfavirenzantirretroviralGrave

    Avoid concomitant use of strong CYP3A4 inhibitors. (bula de Dasatinibe, Interações medicamentosas)

  • Efavirenz + lamivudina + tenofovirantirretroviralGrave

    Avoid concomitant use of strong CYP3A4 inhibitors. (bula de Dasatinibe, Interações medicamentosas)

  • Elvitegravir + cobicistate + entricitabina + tenofovirantirretroviralGrave

    Avoid concomitant use of strong CYP3A4 inhibitors. (bula de Dasatinibe, Interações medicamentosas)

  • Eritromicinaantibiótico macrolídeoGrave

    Avoid concomitant use of strong CYP3A4 inhibitors. (bula de Dasatinibe, Interações medicamentosas)

  • EslicarbazepinaanticonvulsivanteGrave

    If concomitant administration of a strong CYP3A4 inducer cannot be avoided, consider a dose increase [see Dosage and Administration ( 2.3 )] . (bula de Dasatinibe, Interações medicamentosas)

  • EtravirinaantirretroviralGrave

    If concomitant administration of a strong CYP3A4 inducer cannot be avoided, consider a dose increase [see Dosage and Administration ( 2.3 )] . (bula de Dasatinibe, Interações medicamentosas)

  • EverolimoimunossupressorGrave

    Avoid concomitant use of strong CYP3A4 inhibitors. (bula de Dasatinibe, Interações medicamentosas)

  • FenitoínaanticonvulsivanteGrave

    If concomitant administration of a strong CYP3A4 inducer cannot be avoided, consider a dose increase [see Dosage and Administration ( 2.3 )] . (bula de Dasatinibe, Interações medicamentosas)

  • FenobarbitalbarbitúricoGrave

    If concomitant administration of a strong CYP3A4 inducer cannot be avoided, consider a dose increase [see Dosage and Administration ( 2.3 )] . (bula de Dasatinibe, Interações medicamentosas)

  • Fentermina + topiramatoestimulante do SNCGrave

    If concomitant administration of a strong CYP3A4 inducer cannot be avoided, consider a dose increase [see Dosage and Administration ( 2.3 )] . (bula de Dasatinibe, Interações medicamentosas)

  • Fluconazolantifúngico azólicoGrave

    Avoid concomitant use of strong CYP3A4 inhibitors. (bula de Dasatinibe, Interações medicamentosas)

  • FosamprenavirantirretroviralGrave

    Avoid concomitant use of strong CYP3A4 inhibitors. (bula de Dasatinibe, Interações medicamentosas)

  • Fosaprepitantoinibidor da CYP3A4Grave

    Avoid concomitant use of strong CYP3A4 inhibitors. (bula de Dasatinibe, Interações medicamentosas)

  • FosfenitoínaanticonvulsivanteGrave

    If concomitant administration of a strong CYP3A4 inducer cannot be avoided, consider a dose increase [see Dosage and Administration ( 2.3 )] . (bula de Dasatinibe, Interações medicamentosas)

  • GriseofulvinaantifúngicoGrave

    If concomitant administration of a strong CYP3A4 inducer cannot be avoided, consider a dose increase [see Dosage and Administration ( 2.3 )] . (bula de Dasatinibe, Interações medicamentosas)

  • Ibuprofeno + famotidinaAINEGrave

    Intervention Concomitant administration of ibuprofen and famotidine tablet is not recommended with dasatinib, delavirdine mesylate, cefditoren, and fosamprenavir. (bula de Ibuprofeno + famotidina, Interações medicamentosas)

  • Imatinibeinibidor da CYP3A4Grave

    Avoid concomitant use of strong CYP3A4 inhibitors. (bula de Dasatinibe, Interações medicamentosas)

  • IsoniazidaantibióticoGrave

    Avoid concomitant use of strong CYP3A4 inhibitors. (bula de Dasatinibe, Interações medicamentosas)

  • Itraconazolantifúngico azólicoGrave

    Avoid concomitant use of strong CYP3A4 inhibitors. (bula de Dasatinibe, Interações medicamentosas)

  • Ivacaftorinibidor da CYP3A4Grave

    Avoid concomitant use of strong CYP3A4 inhibitors. (bula de Dasatinibe, Interações medicamentosas)

  • LenacapavirantirretroviralGrave

    Avoid concomitant use of strong CYP3A4 inhibitors. (bula de Dasatinibe, Interações medicamentosas)

  • Lopinavir + ritonavirantirretroviralGrave

    Avoid concomitant use of strong CYP3A4 inhibitors. (bula de Dasatinibe, Interações medicamentosas)

  • Lorlatinibeindutor da CYP3A4Grave

    If concomitant administration of a strong CYP3A4 inducer cannot be avoided, consider a dose increase [see Dosage and Administration ( 2.3 )] . (bula de Dasatinibe, Interações medicamentosas)

  • Mifepristonainibidor da CYP3A4Grave

    Avoid concomitant use of strong CYP3A4 inhibitors. (bula de Dasatinibe, Interações medicamentosas)

  • Mirabegronaagonista beta-adrenérgicoGrave

    Avoid concomitant use of strong CYP3A4 inhibitors. (bula de Dasatinibe, Interações medicamentosas)

  • Mitapivateindutor da CYP3A4Grave

    If concomitant administration of a strong CYP3A4 inducer cannot be avoided, consider a dose increase [see Dosage and Administration ( 2.3 )] . (bula de Dasatinibe, Interações medicamentosas)

  • Mitotanoindutor da CYP3A4Grave

    If concomitant administration of a strong CYP3A4 inducer cannot be avoided, consider a dose increase [see Dosage and Administration ( 2.3 )] . (bula de Dasatinibe, Interações medicamentosas)

  • Modafinilaestimulante do SNCGrave

    If concomitant administration of a strong CYP3A4 inducer cannot be avoided, consider a dose increase [see Dosage and Administration ( 2.3 )] . (bula de Dasatinibe, Interações medicamentosas)

  • Nafcilinaantibiótico da classe das penicilinasGrave

    If concomitant administration of a strong CYP3A4 inducer cannot be avoided, consider a dose increase [see Dosage and Administration ( 2.3 )] . (bula de Dasatinibe, Interações medicamentosas)

  • NefazodonaantidepressivoGrave

    Avoid concomitant use of strong CYP3A4 inhibitors. (bula de Dasatinibe, Interações medicamentosas)

  • NevirapinaantirretroviralGrave

    If concomitant administration of a strong CYP3A4 inducer cannot be avoided, consider a dose increase [see Dosage and Administration ( 2.3 )] . (bula de Dasatinibe, Interações medicamentosas)

  • Nirmatrelvir + ritonavirantiviralGrave

    Avoid concomitant use of strong CYP3A4 inhibitors. (bula de Dasatinibe, Interações medicamentosas)

  • Omeprazol + bicarbonato de sódioinibidor da bomba de prótonsGrave

    Antacids: Avoid concomitant use. (bula de Dasatinibe, Interações medicamentosas)

  • OxcarbazepinaanticonvulsivanteGrave

    If concomitant administration of a strong CYP3A4 inducer cannot be avoided, consider a dose increase [see Dosage and Administration ( 2.3 )] . (bula de Dasatinibe, Interações medicamentosas)

  • Palbociclibeinibidor da CYP3A4Grave

    Avoid concomitant use of strong CYP3A4 inhibitors. (bula de Dasatinibe, Interações medicamentosas)

  • PerampanelanticonvulsivanteGrave

    Avoid concomitant use of strong CYP3A4 inhibitors. (bula de Dasatinibe, Interações medicamentosas)

  • Posaconazolantifúngico azólicoGrave

    Avoid concomitant use of strong CYP3A4 inhibitors. (bula de Dasatinibe, Interações medicamentosas)

  • PrimidonaanticonvulsivanteGrave

    If concomitant administration of a strong CYP3A4 inducer cannot be avoided, consider a dose increase [see Dosage and Administration ( 2.3 )] . (bula de Dasatinibe, Interações medicamentosas)

  • Ranolazinamedicamento que prolonga o intervalo QTGrave

    Avoid concomitant use of strong CYP3A4 inhibitors. (bula de Dasatinibe, Interações medicamentosas)

  • RifabutinaantibióticoGrave

    If concomitant administration of a strong CYP3A4 inducer cannot be avoided, consider a dose increase [see Dosage and Administration ( 2.3 )] . (bula de Dasatinibe, Interações medicamentosas)

  • RifampicinaantibióticoGrave

    If concomitant administration of a strong CYP3A4 inducer cannot be avoided, consider a dose increase [see Dosage and Administration ( 2.3 )] . (bula de Dasatinibe, Interações medicamentosas)

  • RifapentinaantibióticoGrave

    If concomitant administration of a strong CYP3A4 inducer cannot be avoided, consider a dose increase [see Dosage and Administration ( 2.3 )] . (bula de Dasatinibe, Interações medicamentosas)

  • RitonavirantirretroviralGrave

    Avoid concomitant use of strong CYP3A4 inhibitors. (bula de Dasatinibe, Interações medicamentosas)

  • Suvorexantosedativo-hipnóticoGrave

    Avoid concomitant use of strong CYP3A4 inhibitors. (bula de Dasatinibe, Interações medicamentosas)

  • Suzetriginaindutor da CYP3A4Grave

    If concomitant administration of a strong CYP3A4 inducer cannot be avoided, consider a dose increase [see Dosage and Administration ( 2.3 )] . (bula de Dasatinibe, Interações medicamentosas)

  • Ticagrelorantiagregante plaquetárioGrave

    Avoid concomitant use of strong CYP3A4 inhibitors. (bula de Dasatinibe, Interações medicamentosas)

  • TopiramatoanticonvulsivanteGrave

    If concomitant administration of a strong CYP3A4 inducer cannot be avoided, consider a dose increase [see Dosage and Administration ( 2.3 )] . (bula de Dasatinibe, Interações medicamentosas)

  • Verapamilbloqueador dos canais de cálcioGrave

    Avoid concomitant use of strong CYP3A4 inhibitors. (bula de Dasatinibe, Interações medicamentosas)

  • Voriconazolantifúngico azólicoGrave

    Avoid concomitant use of strong CYP3A4 inhibitors. (bula de Dasatinibe, Interações medicamentosas)

Interações moderadas (30)

  • AdenosinaantiarrítmicoModerada

    QT Prolongation PHYRAGO may increase the risk of prolongation of QTc in patients including those with hypokalemia or hypomagnesemia, patients with congenital long QT syndrome, patients taking antiarrhythmic medicines or other medicinal products that lead to QT prolongation, and cumulative high-dose anthracycline therapy [see Adverse Reactions ( 6.1 )] . (bula de Dasatinibe, Advertências e precauções)

  • ApixabanaanticoagulanteModerada

    Use caution if used concomitantly with medications that inhibit platelet function or anticoagulants. (bula de Dasatinibe, Advertências e precauções)

  • ArgatrobanaanticoagulanteModerada

    Use caution if used concomitantly with medications that inhibit platelet function or anticoagulants. (bula de Dasatinibe, Advertências e precauções)

  • BivalirudinaanticoagulanteModerada

    Use caution if used concomitantly with medications that inhibit platelet function or anticoagulants. (bula de Dasatinibe, Advertências e precauções)

  • DabigatranaanticoagulanteModerada

    Use caution if used concomitantly with medications that inhibit platelet function or anticoagulants. (bula de Dasatinibe, Advertências e precauções)

  • Dexlansoprazolinibidor da bomba de prótonsModerada

    Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole) Clinical Impact: Dexlansoprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity. (bula de Dexlansoprazol, Interações medicamentosas)

  • Digoxinaglicosídeo digitálicoModerada

    QT Prolongation PHYRAGO may increase the risk of prolongation of QTc in patients including those with hypokalemia or hypomagnesemia, patients with congenital long QT syndrome, patients taking antiarrhythmic medicines or other medicinal products that lead to QT prolongation, and cumulative high-dose anthracycline therapy [see Adverse Reactions ( 6.1 )] . (bula de Dasatinibe, Advertências e precauções)

  • DisopiramidaantiarrítmicoModerada

    QT Prolongation PHYRAGO may increase the risk of prolongation of QTc in patients including those with hypokalemia or hypomagnesemia, patients with congenital long QT syndrome, patients taking antiarrhythmic medicines or other medicinal products that lead to QT prolongation, and cumulative high-dose anthracycline therapy [see Adverse Reactions ( 6.1 )] . (bula de Dasatinibe, Advertências e precauções)

  • DofetilidaantiarrítmicoModerada

    QT Prolongation PHYRAGO may increase the risk of prolongation of QTc in patients including those with hypokalemia or hypomagnesemia, patients with congenital long QT syndrome, patients taking antiarrhythmic medicines or other medicinal products that lead to QT prolongation, and cumulative high-dose anthracycline therapy [see Adverse Reactions ( 6.1 )] . (bula de Dasatinibe, Advertências e precauções)

  • EdoxabanaanticoagulanteModerada

    Use caution if used concomitantly with medications that inhibit platelet function or anticoagulants. (bula de Dasatinibe, Advertências e precauções)

  • EnoxaparinaanticoagulanteModerada

    Use caution if used concomitantly with medications that inhibit platelet function or anticoagulants. (bula de Dasatinibe, Advertências e precauções)

  • EsmololbetabloqueadorModerada

    QT Prolongation PHYRAGO may increase the risk of prolongation of QTc in patients including those with hypokalemia or hypomagnesemia, patients with congenital long QT syndrome, patients taking antiarrhythmic medicines or other medicinal products that lead to QT prolongation, and cumulative high-dose anthracycline therapy [see Adverse Reactions ( 6.1 )] . (bula de Dasatinibe, Advertências e precauções)

  • Esomeprazolinibidor da bomba de prótonsModerada

    Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole) Clinical Impact: Esomeprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity Intervention: Mycophenolate mofetil (MMF): Co-administration of omeprazole, of which esomeprazole… (bula de Esomeprazol, Interações medicamentosas)

  • FlecainidaantiarrítmicoModerada

    QT Prolongation PHYRAGO may increase the risk of prolongation of QTc in patients including those with hypokalemia or hypomagnesemia, patients with congenital long QT syndrome, patients taking antiarrhythmic medicines or other medicinal products that lead to QT prolongation, and cumulative high-dose anthracycline therapy [see Adverse Reactions ( 6.1 )] . (bula de Dasatinibe, Advertências e precauções)

  • FondaparinuxanticoagulanteModerada

    Use caution if used concomitantly with medications that inhibit platelet function or anticoagulants. (bula de Dasatinibe, Advertências e precauções)

  • HeparinaanticoagulanteModerada

    Use caution if used concomitantly with medications that inhibit platelet function or anticoagulants. (bula de Dasatinibe, Advertências e precauções)

  • IbutilidaantiarrítmicoModerada

    QT Prolongation PHYRAGO may increase the risk of prolongation of QTc in patients including those with hypokalemia or hypomagnesemia, patients with congenital long QT syndrome, patients taking antiarrhythmic medicines or other medicinal products that lead to QT prolongation, and cumulative high-dose anthracycline therapy [see Adverse Reactions ( 6.1 )] . (bula de Dasatinibe, Advertências e precauções)

  • Lansoprazolinibidor da bomba de prótonsModerada

    Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole) Clinical Impact: Lansoprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity. (bula de Lansoprazol, Interações medicamentosas)

  • Lidocaínaanestésico localModerada

    QT Prolongation PHYRAGO may increase the risk of prolongation of QTc in patients including those with hypokalemia or hypomagnesemia, patients with congenital long QT syndrome, patients taking antiarrhythmic medicines or other medicinal products that lead to QT prolongation, and cumulative high-dose anthracycline therapy [see Adverse Reactions ( 6.1 )] . (bula de Dasatinibe, Advertências e precauções)

  • Lidocaína + prilocaínaanestésico localModerada

    QT Prolongation PHYRAGO may increase the risk of prolongation of QTc in patients including those with hypokalemia or hypomagnesemia, patients with congenital long QT syndrome, patients taking antiarrhythmic medicines or other medicinal products that lead to QT prolongation, and cumulative high-dose anthracycline therapy [see Adverse Reactions ( 6.1 )] . (bula de Dasatinibe, Advertências e precauções)

  • MexiletinaantiarrítmicoModerada

    QT Prolongation PHYRAGO may increase the risk of prolongation of QTc in patients including those with hypokalemia or hypomagnesemia, patients with congenital long QT syndrome, patients taking antiarrhythmic medicines or other medicinal products that lead to QT prolongation, and cumulative high-dose anthracycline therapy [see Adverse Reactions ( 6.1 )] . (bula de Dasatinibe, Advertências e precauções)

  • Omeprazolinibidor da bomba de prótonsModerada

    Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole) Clinical Impact: Omeprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity. (bula de Omeprazol, Interações medicamentosas)

  • Pantoprazolinibidor da bomba de prótonsModerada

    Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole) Clinical Impact: Pantoprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity. (bula de Pantoprazol, Interações medicamentosas)

  • ProcainamidaantiarrítmicoModerada

    QT Prolongation PHYRAGO may increase the risk of prolongation of QTc in patients including those with hypokalemia or hypomagnesemia, patients with congenital long QT syndrome, patients taking antiarrhythmic medicines or other medicinal products that lead to QT prolongation, and cumulative high-dose anthracycline therapy [see Adverse Reactions ( 6.1 )] . (bula de Dasatinibe, Advertências e precauções)

  • PropafenonaantiarrítmicoModerada

    QT Prolongation PHYRAGO may increase the risk of prolongation of QTc in patients including those with hypokalemia or hypomagnesemia, patients with congenital long QT syndrome, patients taking antiarrhythmic medicines or other medicinal products that lead to QT prolongation, and cumulative high-dose anthracycline therapy [see Adverse Reactions ( 6.1 )] . (bula de Dasatinibe, Advertências e precauções)

  • QuinidinaantiarrítmicoModerada

    QT Prolongation PHYRAGO may increase the risk of prolongation of QTc in patients including those with hypokalemia or hypomagnesemia, patients with congenital long QT syndrome, patients taking antiarrhythmic medicines or other medicinal products that lead to QT prolongation, and cumulative high-dose anthracycline therapy [see Adverse Reactions ( 6.1 )] . (bula de Dasatinibe, Advertências e precauções)

  • Rabeprazolinibidor da bomba de prótonsModerada

    Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole, itraconazole) Clinical Impact: Rabeprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity. (bula de Rabeprazol, Interações medicamentosas)

  • RivaroxabanaanticoagulanteModerada

    Use caution if used concomitantly with medications that inhibit platelet function or anticoagulants. (bula de Dasatinibe, Advertências e precauções)

  • SotalolbetabloqueadorModerada

    QT Prolongation PHYRAGO may increase the risk of prolongation of QTc in patients including those with hypokalemia or hypomagnesemia, patients with congenital long QT syndrome, patients taking antiarrhythmic medicines or other medicinal products that lead to QT prolongation, and cumulative high-dose anthracycline therapy [see Adverse Reactions ( 6.1 )] . (bula de Dasatinibe, Advertências e precauções)

  • VarfarinaanticoagulanteModerada

    Use caution if used concomitantly with medications that inhibit platelet function or anticoagulants. (bula de Dasatinibe, Advertências e precauções)

Menções leves (53)

  • Acetazolamidainibidor da anidrase carbônicaLeve

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (bula de Dasatinibe, Advertências e precauções)

  • Ácido etacrínicodiurético de alçaLeve

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (bula de Dasatinibe, Advertências e precauções)

  • Amiloridadiurético poupador de potássioLeve

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (bula de Dasatinibe, Advertências e precauções)

  • Atenolol + clortalidonabetabloqueadorLeve

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (bula de Dasatinibe, Advertências e precauções)

  • Azelastina + fluticasonaanti-histamínicoLeve

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (bula de Dasatinibe, Advertências e precauções)

  • BeclometasonacorticosteroideLeve

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (bula de Dasatinibe, Advertências e precauções)

  • Benazepril + hidroclorotiazidainibidor da ECALeve

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (bula de Dasatinibe, Advertências e precauções)

  • BetametasonacorticosteroideLeve

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (bula de Dasatinibe, Advertências e precauções)

  • Bisoprolol + hidroclorotiazidabetabloqueadorLeve

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (bula de Dasatinibe, Advertências e precauções)

  • BudesonidacorticosteroideLeve

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (bula de Dasatinibe, Advertências e precauções)

  • Budesonida + formoterolcorticosteroideLeve

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (bula de Dasatinibe, Advertências e precauções)

  • Bumetanidadiurético de alçaLeve

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (bula de Dasatinibe, Advertências e precauções)

  • Candesartana + hidroclorotiazidabloqueador do receptor da angiotensina II (BRA)Leve

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (bula de Dasatinibe, Advertências e precauções)

  • CiclesonidacorticosteroideLeve

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (bula de Dasatinibe, Advertências e precauções)

  • ClobetasolcorticosteroideLeve

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (bula de Dasatinibe, Advertências e precauções)

  • Clorotiazidadiurético tiazídicoLeve

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (bula de Dasatinibe, Advertências e precauções)

  • Clortalidonadiurético tiazídicoLeve

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (bula de Dasatinibe, Advertências e precauções)

  • DeflazacortecorticosteroideLeve

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (bula de Dasatinibe, Advertências e precauções)

  • DesonidacorticosteroideLeve

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (bula de Dasatinibe, Advertências e precauções)

  • Enalapril + hidroclorotiazidainibidor da ECALeve

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (bula de Dasatinibe, Advertências e precauções)

  • Eplerenonaantagonista da aldosteronaLeve

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (bula de Dasatinibe, Advertências e precauções)

  • Espironolactonaantagonista da aldosteronaLeve

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (bula de Dasatinibe, Advertências e precauções)

  • Espironolactona + hidroclorotiazidaantagonista da aldosteronaLeve

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (bula de Dasatinibe, Advertências e precauções)

  • FludrocortisonacorticosteroideLeve

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (bula de Dasatinibe, Advertências e precauções)

  • FlunisolidacorticosteroideLeve

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (bula de Dasatinibe, Advertências e precauções)

  • FluocinonidacorticosteroideLeve

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (bula de Dasatinibe, Advertências e precauções)

  • FluticasonacorticosteroideLeve

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (bula de Dasatinibe, Advertências e precauções)

  • Fluticasona + salmeterolcorticosteroideLeve

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (bula de Dasatinibe, Advertências e precauções)

  • Fosinopril + hidroclorotiazidainibidor da ECALeve

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (bula de Dasatinibe, Advertências e precauções)

  • Furosemidadiurético de alçaLeve

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (bula de Dasatinibe, Advertências e precauções)

  • HalobetasolcorticosteroideLeve

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (bula de Dasatinibe, Advertências e precauções)

  • Hidroclorotiazidadiurético tiazídicoLeve

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (bula de Dasatinibe, Advertências e precauções)

  • HidrocortisonacorticosteroideLeve

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (bula de Dasatinibe, Advertências e precauções)

  • Indapamidadiurético tiazídicoLeve

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (bula de Dasatinibe, Advertências e precauções)

  • Irbesartana + hidroclorotiazidabloqueador do receptor da angiotensina II (BRA)Leve

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (bula de Dasatinibe, Advertências e precauções)

  • Lisinopril + hidroclorotiazidainibidor da ECALeve

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (bula de Dasatinibe, Advertências e precauções)

  • Losartana + hidroclorotiazidabloqueador do receptor da angiotensina II (BRA)Leve

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (bula de Dasatinibe, Advertências e precauções)

  • MetilprednisolonacorticosteroideLeve

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (bula de Dasatinibe, Advertências e precauções)

  • Metolazonadiurético tiazídicoLeve

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (bula de Dasatinibe, Advertências e precauções)

  • Metoprolol + hidroclorotiazidabetabloqueadorLeve

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (bula de Dasatinibe, Advertências e precauções)

  • MometasonacorticosteroideLeve

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (bula de Dasatinibe, Advertências e precauções)

  • Olmesartana + anlodipino + hidroclorotiazidabloqueador do receptor da angiotensina II (BRA)Leve

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (bula de Dasatinibe, Advertências e precauções)

  • Olmesartana + hidroclorotiazidabloqueador do receptor da angiotensina II (BRA)Leve

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (bula de Dasatinibe, Advertências e precauções)

  • Olopatadina + mometasonaanti-histamínicoLeve

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (bula de Dasatinibe, Advertências e precauções)

  • PrednisolonacorticosteroideLeve

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (bula de Dasatinibe, Advertências e precauções)

  • PrednisonacorticosteroideLeve

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (bula de Dasatinibe, Advertências e precauções)

  • Quinapril + hidroclorotiazidainibidor da ECALeve

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (bula de Dasatinibe, Advertências e precauções)

  • Telmisartana + hidroclorotiazidabloqueador do receptor da angiotensina II (BRA)Leve

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (bula de Dasatinibe, Advertências e precauções)

  • Torasemidadiurético de alçaLeve

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (bula de Dasatinibe, Advertências e precauções)

  • TriancinolonacorticosteroideLeve

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (bula de Dasatinibe, Advertências e precauções)

  • Trianterenodiurético poupador de potássioLeve

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (bula de Dasatinibe, Advertências e precauções)

  • Triantereno + hidroclorotiazidadiurético poupador de potássioLeve

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (bula de Dasatinibe, Advertências e precauções)

  • Valsartana + hidroclorotiazidabloqueador do receptor da angiotensina II (BRA)Leve

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (bula de Dasatinibe, Advertências e precauções)

Verifique Dasatinibe com tudo o que você toma. Adicione sua lista completa; todos os pares são verificados de uma vez.

Abrir no verificador

Não é aconselhamento médico. A gravidade reflete a redação da bula, não as suas circunstâncias. Um alerta “grave” pode ser rotina sob supervisão, e um “leve” pode ser importante em doses altas. Pergunte a um farmacêutico.